Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11355645 | 0.89 | POLB (0.55) | MAPTGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7593370 | 0.86 | MEN1 (0.51) | MAPTGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1120688 | 0.85 | MAPT (0.59) | MAPTGAATRPV1ALDH1A1LMNA | |
| SCHEMBL1751588 | 0.85 | MAPT (0.56) | MAPTGAATRPV1ALDH1A1LMNA | |
| SCHEMBL29860111 | 0.84 | MAPT (0.53) | MAPTGAAALDH1A1LMNAHTT | |
| SCHEMBL8168563 | 0.84 | MAPT (0.53) | MAPTGAAALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL15646288 | 0.84 | MEN1 (0.50) | MAPTGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL9271365 | 0.84 | HTT (0.50) | MAPTGAATRPV1ALDH1A1LMNA | |
| SCHEMBL6239200 | 0.84 | KMT2A (0.47) | MAPTGAAALDH1A1LMNAKDM4E | |
| SCHEMBL11729327 | 0.84 | MEN1 (0.51) | MAPTGAAALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049804-A1 | FERROCHELATASE INHIBITORS AND METHODS OF USE | UNIV INDIANA RES & TECH CORP (US) | 2025-02-13 | — | — | US | disclosed |
| US-12161642-B2 | Ferrochelatase inhibitors and methods of use | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2024-12-10 | — | — | US | disclosed |
| CN-110372627-B | 1,3, 4-oxadiazole derivative and preparation method and application thereof | 南昌大学 | 2022-12-06 | — | — | CN | disclosed |
| US-20210121465-A1 | FERROCHELATASE INHIBITORS AND METHODS OF USE | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2021-04-29 | — | — | US | disclosed |
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007008942-A2 | PHENYLAMINO-ACETIC ACID [1-(PYRIDIN-4-YL)-METHYLIDENE]-HYDRAZIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF G PROTEIN-COUPLED RECEPTOR KINASES FOR THE TREATMENT OF EYE DISEASES | AERIE PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-4237132-A | ARTERIOSCLEROSIS, ANTICHOLESTEROL, ANTILIPEMIC | NIPPON SHINYAKU CO., LTD. (JP) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049804-A1 | FERROCHELATASE INHIBITORS AND METHODS OF USE | FECH, SLC40A1, TPI1 | MAPT 3197/4885GAA 170/4885TRPV1 2992/4885 |
| US-20070135499-A1 | Hydrazide compounds | GRK4, GRK2, GRK1 | MAPT 3473/4885GAA 997/4885TRPV1 108/4885 |
| US-20210121465-A1 | FERROCHELATASE INHIBITORS AND METHODS OF USE | FECH, SLC40A1, TPI1 | MAPT 3197/4885GAA 170/4885TRPV1 2992/4885 |
| US-12161642-B2 | Ferrochelatase inhibitors and methods of use | FECH, SLC40A1, TPI1 | MAPT 3197/4885GAA 170/4885TRPV1 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.